Trial Profile
A Prospective, Double Blind, Randomized, Placebo-Controlled Phase III Trial of Imatinib Re-Challenge in Patients With Gastrointestinal Stromal Tumor Who Had Benefit From Prior Imatinib But Progression From Both Imatinib and Sunitinib.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Acronyms RIGHT
- Sponsors Novartis Oncology
- 14 Dec 2015 Results of sub-analysis published in the European Journal of Cancer
- 17 Oct 2013 Results published in the Lancet Oncology.
- 31 May 2013 Primary endpoint 'Progression-free-survival-duration' has been met.